Ocrelizumab exposure in the second trimester of pregnancy without neonatal B-cell depletion.

Rolfes, Mary; Rutatangwa, Alice; Waubant, Emmanuelle; Krysko, Kristen M

Rolfes, Mary; Rutatangwa, Alice; Waubant, Emmanuelle; Krysko, Kristen M.

Afiliação

Rolfes M; Department of Pediatrics, University of California San Francisco, 550 16th Street, San Francisco CA 94158, United States. Electronic address: Mary.rolfes@ucsf.edu.
Rutatangwa A; UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, 675 Nelson Rising Lane, San Francisco CA 94158, United States. Electronic address: Alice.rutatangwa@ucsf.edu.
Waubant E; UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, 675 Nelson Rising Lane, San Francisco CA 94158, United States. Electronic address: Emmanuelle.waubant@ucsf.edu.
Krysko KM; UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, 675 Nelson Rising Lane, San Francisco CA 94158, United States. Electronic address: kristen.krysko@mail.utoronto.ca.

Mult Scler Relat Disord ; 45: 102398, 2020 Oct.

Article em En | MEDLINE | ID: mdl-32707531

Assuntos

Esclerose Múltipla Recidivante-Remitente; Anticorpos Monoclonais Humanizados/efeitos adversos; Linfócitos B; Criança; Feminino; Humanos; Recém-Nascido; Esclerose Múltipla Recidivante-Remitente/tratamento farmacológico; Gravidez; Segundo Trimestre da Gravidez

Palavras-chave

B-cells; Disease-modifying therapy; Multiple sclerosis; Ocrelizumab; Pregnancy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Recidivante-Remitente Limite: Child / Female / Humans / Newborn / Pregnancy Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google